

# INDOCO REMEDIES LIMITED

Regd. Office: Indoco House, 166 CST Road, Kalina, Santacruz (East), Mumbai - 400098 Tel: +91-22-2654 1851/55 Fax: +91-22- 66936241

## PART-I UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2013 (₹ In Lacs)

Sr. No.	Particulars	Quarter ended 30.06.2013 (Unaudited)	Quarter ended 31.03.2013 (Unaudited)	Quarter ended 30.06.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
<b>1</b>	<b>Income from Operations</b>				
	(a) Gross Sales / Income from Operations	15,092	16,325	15,352	63,767
	(b) Less : Excise Duty	(287)	(277)	(236)	(1,124)
	(c) Net Sales / Income from Operations (a-b)	14,805	16,048	15,116	62,643
	(d) Other Operating Income	590	(145)	492	397
	<b>Total Income from Operations (Net) (c+d)</b>	<b>15,395</b>	<b>15,903</b>	<b>15,608</b>	<b>63,040</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	5,279	5,069	6,096	22,328
	(b) Purchases of stock-in-trade	974	801	1,017	3,555
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(285)	515	(501)	313
	(d) Employee Benefits expense	2,635	2,502	2,330	10,031
	(e) Depreciation and Amortisation expense	733	625	581	2,372
	(f) Research & Development expense	274	279	365	1,290
	(g) Other Expenses	4,081	4,194	3,744	16,215
	<b>Total Expenses</b>	<b>13,691</b>	<b>13,985</b>	<b>13,632</b>	<b>56,104</b>
<b>3</b>	<b>Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>1,704</b>	<b>1,918</b>	<b>1,976</b>	<b>6,936</b>
4	Other Income	15	17	15	89
<b>5</b>	<b>Profit from Ordinary activities before Finance Cost and Exceptional Items (3+4)</b>	<b>1,719</b>	<b>1,935</b>	<b>1,991</b>	<b>7,025</b>
6	Finance Costs	620	509	821	2,188
<b>7</b>	<b>Profit from Ordinary activities after Finance Cost but before Exceptional Items (5-6)</b>	<b>1,099</b>	<b>1,426</b>	<b>1,170</b>	<b>4,837</b>
8	Exceptional Items	-	-	-	-
<b>9</b>	<b>Profit from Ordinary activities before tax (7-8)</b>	<b>1,099</b>	<b>1,426</b>	<b>1,170</b>	<b>4,837</b>
10	Tax Expenses - Current	220	286	234	968
	- Deferred	177	113	135	543
	- Prior Year	4	28	-	28
	- MAT Credit	(220)	(286)	(234)	(968)
<b>11</b>	<b>Net Profit from Ordinary activities after tax (9-10)</b>	<b>918</b>	<b>1,285</b>	<b>1,035</b>	<b>4,266</b>
12	Extraordinary Items	-	-	-	-
<b>13</b>	<b>Net Profit for the period (11-12)</b>	<b>918</b>	<b>1,285</b>	<b>1,035</b>	<b>4,266</b>
14	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843
15	Reserves excluding Revaluation Reserves as per Balance Sheet of Previous accounting year	-	-	-	39,561
<b>16</b>	<b>Earnings per share (before and after extraordinary items) (of ₹ 2/- each) (not annualised):</b>				
	(a) Basic	1.00	1.39	1.12	4.63
	(b) Diluted	1.00	1.39	1.12	4.63

**PART II SELECT INFORMATION FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2013**

Sr. No.	Particulars	Quarter ended 30.06.2013 (Unaudited)	Quarter ended 31.03.2013 (Unaudited)	Quarter ended 30.06.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public shareholding				
	- Number of Shares	<b>376,06,815</b>	376,05,715	376,05,715	<b>376,05,715</b>
	- Percentage of Shareholding	<b>40.81</b>	40.81	40.81	<b>40.81</b>
2	Promoters and promoter group shareholding				
	<b>a) Pledged/Encumbered</b>				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	<b>b) Non-encumbered</b>				
	- Number of shares	<b>545,43,540</b>	545,44,640	545,44,640	<b>545,44,640</b>
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00	100.00	<b>100.00</b>
	- Percentage of shares (as a % of the total share capital of the company)	<b>59.19</b>	59.19	59.19	<b>59.19</b>
<b>Sr. No.</b>	<b>Particulars</b>	<b>3 months ended 30.06.2013</b>			
<b>B</b>	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter	<b>Nil</b>			
	Received during the quarter	<b>2</b>			
	Disposed off during the quarter	<b>2</b>			
	Remaining unresolved at the end of the quarter	<b>Nil</b>			

**Notes :**

1 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

**Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:**

(₹ In Lacs)

Net Sales and Income from Operations	Quarter ended 30.06.2013 (Unaudited)	Quarter ended 31.03.2013 (Unaudited)	Quarter ended 30.06.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
India	<b>10,401</b>	9,693	9,762	<b>40,772</b>
Outside India	<b>4,404</b>	6,355	5,354	<b>21,871</b>
<b>Total</b>	<b>14,805</b>	16,048	15,116	<b>62,643</b>

2 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

3 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on July 30, 2013.

4 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended June 30, 2013.

**By Order of the Board  
For Indoco Remedies Ltd  
Sd/-  
Suresh G Kare  
Chairman**

Place : Mumbai

Date : July 30, 2013